Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 26

1.

Structure and Functions of Microtubule Associated Proteins Tau and MAP2c: Similarities and Differences.

Melková K, Zapletal V, Narasimhan S, Jansen S, Hritz J, Škrabana R, Zweckstetter M, Ringkjøbing Jensen M, Blackledge M, Žídek L.

Biomolecules. 2019 Mar 16;9(3). pii: E105. doi: 10.3390/biom9030105. Review.

2.

A walk through tau therapeutic strategies.

Jadhav S, Avila J, Schöll M, Kovacs GG, Kövari E, Skrabana R, Evans LD, Kontsekova E, Malawska B, de Silva R, Buee L, Zilka N.

Acta Neuropathol Commun. 2019 Feb 15;7(1):22. doi: 10.1186/s40478-019-0664-z. Review.

3.

Tau Conformation as a Target for Disease-Modifying Therapy: The Role of Truncation.

Novak P, Cehlar O, Skrabana R, Novak M.

J Alzheimers Dis. 2018;64(s1):S535-S546. doi: 10.3233/JAD-179942.

PMID:
29865059
4.

Lactoferrin is a natural inhibitor of plasminogen activation.

Zwirzitz A, Reiter M, Skrabana R, Ohradanova-Repic A, Majdic O, Gutekova M, Cehlar O, Petrovčíková E, Kutejova E, Stanek G, Stockinger H, Leksa V.

J Biol Chem. 2018 Jun 1;293(22):8600-8613. doi: 10.1074/jbc.RA118.003145. Epub 2018 Apr 18.

PMID:
29669808
5.

Neuronal Expression of Truncated Tau Efficiently Promotes Neurodegeneration in Animal Models: Pitfalls of Toxic Oligomer Analysis.

Skrabana R, Kovacech B, Filipcik P, Zilka N, Jadhav S, Smolek T, Kontsekova E, Novak M.

J Alzheimers Dis. 2017;58(4):1017-1025. doi: 10.3233/JAD-161124.

PMID:
28527208
6.

Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial.

Novak P, Schmidt R, Kontsekova E, Zilka N, Kovacech B, Skrabana R, Vince-Kazmerova Z, Katina S, Fialova L, Prcina M, Parrak V, Dal-Bianco P, Brunner M, Staffen W, Rainer M, Ondrus M, Ropele S, Smisek M, Sivak R, Winblad B, Novak M.

Lancet Neurol. 2017 Feb;16(2):123-134. doi: 10.1016/S1474-4422(16)30331-3. Epub 2016 Dec 10.

PMID:
27955995
7.

Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease.

Kontsekova E, Zilka N, Kovacech B, Skrabana R, Novak M.

Alzheimers Res Ther. 2014 Aug 1;6(4):45. doi: 10.1186/alzrt277. eCollection 2014.

8.

N-terminal truncation of microtubule associated protein tau dysregulates its cellular localization.

Paholikova K, Salingova B, Opattova A, Skrabana R, Majerova P, Zilka N, Kovacech B, Zilkova M, Barath P, Novak M.

J Alzheimers Dis. 2015;43(3):915-26. doi: 10.3233/JAD-140996.

PMID:
25147106
9.

Crystallization and preliminary X-ray diffraction analysis of two peptides from Alzheimer PHF in complex with the MN423 antibody Fab fragment.

Skrabana R, Cehlar O, Flachbartova Z, Kovac A, Sevcik J, Novak M.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2012 Oct 1;68(Pt 10):1186-90. doi: 10.1107/S1744309112033477. Epub 2012 Sep 25.

10.

Crystallization and preliminary X-ray diffraction analysis of tau protein microtubule-binding motifs in complex with Tau5 and DC25 antibody Fab fragments.

Cehlar O, Skrabana R, Kovac A, Kovacech B, Novak M.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2012 Oct 1;68(Pt 10):1181-5. doi: 10.1107/S1744309112030382. Epub 2012 Sep 25.

11.

The structure and interactions of SpoIISA and SpoIISB, a toxin-antitoxin system in Bacillus subtilis.

Florek P, Levdikov VM, Blagova E, Lebedev AA, Škrabana R, Resetárová S, Pavelcíková P, Barak I, Wilkinson AJ.

J Biol Chem. 2011 Feb 25;286(8):6808-19. doi: 10.1074/jbc.M110.172429. Epub 2010 Dec 7.

12.

Hyperphosphorylated truncated protein tau induces caspase-3 independent apoptosis-like pathway in the Alzheimer's disease cellular model.

Zilkova M, Zilka N, Kovac A, Kovacech B, Skrabana R, Skrabanova M, Novak M.

J Alzheimers Dis. 2011;23(1):161-9. doi: 10.3233/JAD-2010-101434.

PMID:
20966551
13.

Monoclonal antibody MN423 as a stable mold facilitates structure determination of disordered tau protein.

Skrabana R, Dvorsky R, Sevcik J, Novak M.

J Struct Biol. 2010 Jul;171(1):74-81. doi: 10.1016/j.jsb.2010.02.016. Epub 2010 Feb 23.

PMID:
20184958
14.

Transition of tau protein from disordered to misordered in Alzheimer's disease.

Kovacech B, Skrabana R, Novak M.

Neurodegener Dis. 2010;7(1-3):24-7. doi: 10.1159/000283478. Epub 2010 Feb 13.

PMID:
20160453
15.

Novel mutations in TLR genes cause hyporesponsiveness to Mycobacterium avium subsp. paratuberculosis infection.

Bhide MR, Mucha R, Mikula I Jr, Kisova L, Skrabana R, Novak M, Mikula I Sr.

BMC Genet. 2009 May 26;10:21. doi: 10.1186/1471-2156-10-21.

16.

Structure solution of misfolded conformations adopted by intrinsically disordered Alzheimer's tau protein.

Sevcik J, Skrabana R, Kontsekova E, Novak M.

Protein Pept Lett. 2009;16(1):61-4.

PMID:
19149675
17.

A global benchmark study using affinity-based biosensors.

Rich RL, Papalia GA, Flynn PJ, Furneisen J, Quinn J, Klein JS, Katsamba PS, Waddell MB, Scott M, Thompson J, Berlier J, Corry S, Baltzinger M, Zeder-Lutz G, Schoenemann A, Clabbers A, Wieckowski S, Murphy MM, Page P, Ryan TE, Duffner J, Ganguly T, Corbin J, Gautam S, Anderluh G, Bavdek A, Reichmann D, Yadav SP, Hommema E, Pol E, Drake A, Klakamp S, Chapman T, Kernaghan D, Miller K, Schuman J, Lindquist K, Herlihy K, Murphy MB, Bohnsack R, Andrien B, Brandani P, Terwey D, Millican R, Darling RJ, Wang L, Carter Q, Dotzlaf J, Lopez-Sagaseta J, Campbell I, Torreri P, Hoos S, England P, Liu Y, Abdiche Y, Malashock D, Pinkerton A, Wong M, Lafer E, Hinck C, Thompson K, Primo CD, Joyce A, Brooks J, Torta F, Bagge Hagel AB, Krarup J, Pass J, Ferreira M, Shikov S, Mikolajczyk M, Abe Y, Barbato G, Giannetti AM, Krishnamoorthy G, Beusink B, Satpaev D, Tsang T, Fang E, Partridge J, Brohawn S, Horn J, Pritsch O, Obal G, Nilapwar S, Busby B, Gutierrez-Sanchez G, Gupta RD, Canepa S, Witte K, Nikolovska-Coleska Z, Cho YH, D'Agata R, Schlick K, Calvert R, Munoz EM, Hernaiz MJ, Bravman T, Dines M, Yang MH, Puskas A, Boni E, Li J, Wear M, Grinberg A, Baardsnes J, Dolezal O, Gainey M, Anderson H, Peng J, Lewis M, Spies P, Trinh Q, Bibikov S, Raymond J, Yousef M, Chandrasekaran V, Feng Y, Emerick A, Mundodo S, Guimaraes R, McGirr K, Li YJ, Hughes H, Mantz H, Skrabana R, Witmer M, Ballard J, Martin L, Skladal P, Korza G, Laird-Offringa I, Lee CS, Khadir A, Podlaski F, Neuner P, Rothacker J, Rafique A, Dankbar N, Kainz P, Gedig E, Vuyisich M, Boozer C, Ly N, Toews M, Uren A, Kalyuzhniy O, Lewis K, Chomey E, Pak BJ, Myszka DG.

Anal Biochem. 2009 Mar 15;386(2):194-216. doi: 10.1016/j.ab.2008.11.021. Epub 2008 Nov 27.

18.

Preserving free thiols of intrinsically disordered tau protein without the use of a reducing agent.

Krajciova G, Skrabana R, Filipcik P, Novak M.

Anal Biochem. 2008 Dec 15;383(2):343-5. doi: 10.1016/j.ab.2008.09.022. Epub 2008 Sep 20.

PMID:
18834853
19.

X-ray structure of the PHF core C-terminus: insight into the folding of the intrinsically disordered protein tau in Alzheimer's disease.

Sevcik J, Skrabana R, Dvorsky R, Csokova N, Iqbal K, Novak M.

FEBS Lett. 2007 Dec 22;581(30):5872-8. Epub 2007 Dec 3.

20.

A novel monoclonal antibody DC63 reveals that inhibitor 1 of protein phosphatase 2A is preferentially nuclearly localised in human brain.

Kovacech B, Kontsekova E, Zilka N, Novak P, Skrabana R, Filipcik P, Iqbal K, Novak M.

FEBS Lett. 2007 Feb 20;581(4):617-22. Epub 2007 Jan 18.

Supplemental Content

Loading ...
Support Center